Development, LLC (Janssen) today announced it has submitted a New
Drug Application (NDA) to the U.S. Food and
Drug Administration (FDA) seeking approval for simeprevir (TMC435), an investigational NS3/4A protease inhibitor.
Both sofosbuvir and simeprevir are the same class NS3 (whatever it means), so adding them may not be effective, similar to adding invicek and victrelis.